*Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecium

†Clinical significance unknown ‡In an ex-vivo study, more load in N was required to create a 3±1 mm gap between skin edges

approximated with DERMABOND PRINEO System, than with subcuticular 4-0 MONOCRYLTM Suture or PROXIMATE Ethicon Endo-Surgery skin staples (p=0.00).

For illlustrative purposes only

Powerful combination of 2-octyl cyanoacrylate (2-OCA) and self-adhering mesh

Protection• Provides a flexible microbial barrier with 99% protection in vitro for 72 hours against organisms

commonly responsible for SSIs.1*

– Demonstrates in vitro inhibition of gram-positive (MRSA and MRSE) and gram-negative bacteria (E. coli)2†

Strength• statistically significant greater skin holding strength than skin staples or subcuticular 4-0 MONOCRYLTM

(poliglecaprone 25) suture.4‡

• Redistributes tension away from the wound to the surrounding healthy surface area10

Patient Satisfaction• Patient may be able to shower immediately after the procedure, if directed by the healthcare

professional5

• At the time of removal, DERMABOND™ PRINEO™ System is associated with less pain than other wound closure devices6

• No post-surgical dressings may mean easier self-care and greater self-confidence for patients7

Dermabond™

Beyond sutures and staples lies a more innovative solutionDERMABOND™ PRINEO™ Skin Closure System (22 cm)

DERMABOND™ PRINEO™ Skin Closure System (22 cm) was shown to be*:• ~33% stronger when compared

to the average strength of staples3

• ~40% stronger when compared to the average strength of 4-0 suture3

Technology that provides greater strength and a more uniform distribution of tension than skin staples or suture10,*

Please refer always to the Instructions for Use / Package Insert that come with the device for the most current and complete instructions.* Study performed ex vivo. # Premier Inpatient Database in Total Knee Arthroplasty (p<0.05). N=1,942; 2010-2015

References: 1. Ethicon Inc, 06TR071 [Study Report for in vitro evaluation of microbial barrier properties of DERMABOND™ ProTape ], December 2006, Data on File. 2. Ethicon Inc, Notebook 4203:96-100, [In-vitro study to evaluate the ability of PRINEO™ Skin Closure System to kill bacteria on contact ] June 2012, Data on File. 3. Ethicon Inc, AST-2014-0246, Study to compare the tissue holding strength of DERMABOND™ PRINEO™ 22 cm Skin Closure System (DP22) to conventional wound closure techniques, September 2014, Data on File. 4. Ethicon Inc, AST-2012-0290, Study to Compare the tissue holding strength of PRINEO™ skin closure system with conventional wound closure techniques, October 2012, Data on File. 5. DERMABOND™ PRINEO™ Skin Closure System, Instructions for Use. 6. Parvizi D, Friedl H, Schintler MV, et al. Use of 2-Octyl Cyanoacrylate Together with a Self-Adhering Mesh (Dermabond™ Prineo™) for Skin Closure Following Abdominoplasty: An Open, Prospective, Controlled, Randomized Clinical Study. Aesth Plast Surg. 2013;37:529-537. 7. De Cock E, F, Mueller K, Tan R. Changing the surgical wound closure management pathway: time and supplies with PRINEO vs. standard of care for abdominoplasy surgery in Germany. Poster presented at: International Society for Pharmaocoeconomics and Outcomes Research, 11th Annual European Congress: November 2008; Athens, Greece. 8. Ethicion Inc, RWE16_ETH_012, Stratafix Prineo TKA Premier Study Results, Jan 2017, Data on File. 9. Ethicion Inc, CUSR0000SAM, Costs of Index Stay and 30-day Readmissions for Hip and Knee Replacements, Jan 2017, Data on File. 10. Ethicon Inc, 055548-170412, EMEA DERMABOND PRINEO System claims Matrix, April 2017, Data on File. [054526-160609, 054635-160610]

DERMABOND™ PRINEO™ System may improve total knee arthroplasty (TKA) outcomesBased on a retrospective analysis of 1,942 TKA procedures, DERMABOND™ PRINEO™ System was associated with statistically significant reduced length of hospital stay, reduced probability of discharge to skilled nursing facility (SNF) or other non-home setting, and reduced readmission rates when compared to skin staples.8

Mea

n m

ax lo

ad (N

) p

rio

r to

3 m

m g

ap (+

/- 1

mm

)

200

175

150

125

100

75

50

25

0Skin Staples 4-0 Subcuticular

SutureDERMABOND™ PRINEO™

SKIN CLOSURE SYSTEM (22 cm)

166.53

112.498.69

COMPARATIVE SKIN-HOLDING STRENGTHS3,*

Ethicon Endo-Surgery (Europe) GmbHHummelsbütteler Steindamm 71

22851 Norderstedt, Germany

www.ethicon.com

© Ethicon Endo-Surgery (Europe) GmbH 2017, 070989-170412 EMEA

30-Day 60-Day 90-Day

4.4%

1.8%

5.4%

3.0%

7.4%

5.4%

0

2

4

6

8

DERMABOND™ PRINEO™ SystemSkin Staples

30, 60, 90-DAY ALL-CAUSE READMISSION RATES8, #

$12,8399 Potential cost savings by avoiding readmission within 30 days of TKA

Reduced length of stay8

12% reductionwith DERMABOND PRINEO System

Reduced dischargeto non-home setting8

31% reductionwith DERMABOND PRINEO System

Reduced length of stay8

12% reductionwith DERMABOND PRINEO System

Reduced dischargeto non-home setting8

31% reductionwith DERMABOND PRINEO Systemwith DERMABOND™ PRINEO™ System8

12% reductionin length of stay in discharge to non-home setting

31% reductionwith DERMABOND™ PRINEO™ System8